Luminex Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
News Mar 31, 2015
Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay.
"We are excited to announce the start of ARIES clinical trials as planned, which represents a key milestone in our commercial launch schedule," said Homi Shamir, President and CEO of Luminex.
Shamir continued, "Because we designed ARIES to be an easy to use solution that solves many of the problems and challenges laboratories face each day, we are highly optimistic in the market potential for this innovative platform. We continue to advance along our projected launch schedule, and expect to initiate clinical trials for additional ARIES assays in the coming months. With ARIES, we are solidifying a platform which we expect will accelerate growth for years to come."
The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.
Hunger Hormones: A Promising Avenue for Addiction Treatment?News
Hormones that signal the body's state of hunger and fullness could be the key to new treatments for drug and alcohol addiction. Researchers expressed optimism about the potential for rapid progress toward new addiction treatments, since several drugs that affect these hormones are already approved or in the FDA pipeline.READ MORE
Sex Differences Revealed: Heart Failure Death RatesNews
Death from heart failure in men and women compared in a study of over 90 000 patientsREAD MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019